Major VTE events bilateral ascending venography1 · patients with prevention of venous thromboembolism following total hip or knee replacement
Direct thrombin inhibitors showed no clear difference in major VTE events bilateral ascending venography1 compared with low molecular weight heparins (low certainty).
1 finding from 1 review
All‐cause Mortality events · patients with prevention of venous thromboembolism following total hip or knee replacement
Direct thrombin inhibitors probably leads to higher all‐cause Mortality events compared with low molecular weight heparins (moderate certainty).
1 finding from 1 review
Total Bleeding events · patients with prevention of venous thromboembolism following total hip or knee replacement
Direct thrombin inhibitors showed no clear difference in total Bleeding events compared with low molecular weight heparins (low certainty).
1 finding from 1 review
ALT >3 times the upper normal limit · patients with prevention of venous thromboembolism following total hip or knee replacement
Direct thrombin inhibitors may leads to lower ALT >3 times the upper normal limit compared with low molecular weight heparins (low certainty).
1 finding from 1 review
Major VTE events in TKR combined doses bilateral ascending venography · patients with prevention of venous thromboembolism following total hip or knee replacement
Direct thrombin inhibitors showed no clear difference in major VTE events in TKR combined doses bilateral ascending venography compared with vitamin K antagonists (low certainty).
1 finding from 1 review
All‐cause Mortality events in TKR combined doses · patients with prevention of venous thromboembolism following total hip or knee replacement
Direct thrombin inhibitors showed no clear difference in all‐cause Mortality events in TKR combined doses compared with vitamin K antagonists (low certainty).
1 finding from 1 review
Total Bleeding events in TKR combined doses · patients with prevention of venous thromboembolism following total hip or knee replacement
Direct thrombin inhibitors showed no clear difference in total Bleeding events in TKR combined doses compared with vitamin K antagonists (low certainty).
1 finding from 1 review
ALT >3 times the upper normal limit · patients with prevention of venous thromboembolism following total hip or knee replacement
Direct thrombin inhibitors showed no clear difference in ALT >3 times the upper normal limit at the end of compared with vitamin K antagonists (low certainty).
1 finding from 1 review
Recurrent PE · patients with a pulmonary embolism, confirmed by standard imaging techniques
Oral direct thrombin inhibitors (DTIs) showed no clear difference in recurrent PEa compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
Recurrent VTEc · patients with a pulmonary embolism, confirmed by standard imaging techniques
Oral direct thrombin inhibitors (DTIs) showed no clear difference in recurrent VTEc compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
DVTd · patients with a pulmonary embolism, confirmed by standard imaging techniques
Oral direct thrombin inhibitors (DTIs) showed no clear difference in DVTd compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
All‐cause mortality · patients with a pulmonary embolism, confirmed by standard imaging techniques
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major bleedinge · patients with a pulmonary embolism, confirmed by standard imaging techniques
Oral direct thrombin inhibitors (DTIs) showed no clear difference in major bleedinge compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
Health‐related quality of life · patients with a pulmonary embolism, confirmed by standard imaging techniques
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐fatal PE (3 to 12 months) · participants with diagnosed DVT
Oral factor Xa inhibitors showed no clear difference in non‐fatal PE (3 to 12 months) compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
All‐cause mortality (3 to 6 months) · participants with diagnosed DVT
Oral factor Xa inhibitors showed no clear difference in all‐cause mortality (3 to 6 months) compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
Major bleeding · participants with diagnosed DVT
Oral factor Xa inhibitors leads to lower major bleeding (3 to 12 months) compared with conventional anticoagulation (high certainty).
1 finding from 1 review
Recurrent VTE · participants with diagnosed DVT
Oral factor Xa inhibitors showed no clear difference in recurrent VTE (3 to 12 months) compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
Recurrent DVT (3 to 12 months) · participants with diagnosed DVT
Oral factor Xa inhibitors showed no clear difference in recurrent DVT (3 to 12 months) compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
Fatal PE (3 to 12 months) · participants with diagnosed DVT
Oral factor Xa inhibitors showed no clear difference in fatal PE (3 to 12 months) compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review